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Ganoderic acid A (GAA), a representative active triterpenoid from Ganoderma lucidum,
has been reported to exhibit antinociceptive, antioxidative, cytotoxic, hepatoprotective
and anticancer activities. The present study aims (1) to identify GAA metabolites, in vivo
by analyzing the bile, plasma and urine after intravenous administration to rats (20mg/kg),
and in vitro by incubating with rat liver microsomes (RLMs) and human liver microsomes
(HLMs); (2) to investigate the metabolic kinetics of main GAA metabolites. Using HPLC-
DAD-MS/MS techniques, a total of 37 metabolites were tentatively characterized from
in vivo samples based on their fragmentation behaviors. The metabolites detected in in
vitro samples were similar to those found in vivo. GAA underwent extensive phase I and II
metabolism. Themain metabolic soft spots of GAAwere 3, 7, 11, 15, 23-carbonyl groups
(or hydroxyl groups) and 12, 20, 28 (29)-carbon atoms. Ganoderic acid C2 (GAC2) and
7β,15-dihydroxy-3,11,23-trioxo-lanost-26-oic acid were two main reduction metabolites
of GAA, and their kinetics followed classical hyperbolic kinetics. The specific isoenzyme
responsible for the biotransformation of the two metabolites in RLMs and HLMs was
CYP3A. This is the first report on the comprehensive metabolism of GAA, as well as the
metabolic kinetics of its main metabolites.
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INTRODUCTION
Ganoderma lucidum (GL), an ancient remedy, has been used for increasing energy, improving
immunity, and promoting health and longevity for over 2,000 years in Asian countries, particularly
China, Japan and Korea (Wang et al., 2007). GL is commonly used as a dietary supplement or
prescription in clinics to cure many diseases. Polysaccharides and triterpenoids are its two main
types of components and considered to be responsible for the most of its pharmacological activities
(Cheng P.-G. et al., 2013). Triterpenoids are highly oxygenated lanostane. Up to now, more than
140 triterpenoids have been isolated from the fruiting bodies, spores and mycelia of GL (Guo X.-Y.
et al., 2013). Ganoderic acid A (GAA), generally exists in Ganoderma genus, is one of the most
abundant triterpenoids of GL, and can be viewed as a marker component for evaluating GL quality
Abbreviations: EPI, Enhanced product ion; ER, enhanced resolution; HLMs, human liver microsomes; IDA, independent
data acquisition; GAA, ganoderic acid A; GLA, glycyrrhizic acid; MRM, multiple reaction monitoring; RLMs, rat liver
microsomes; UDPGA, uridine 5′-diphosphoglucuronic acid; NADPH, β-Nicotinamide adenine dinucleotide phosphate.
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(Zhao et al., 2006; Lu et al., 2012). In a previous study, GAA was
chosen as the single reference substance for multiple components
determination for quantity control of GL (Da et al., 2015).
GAA reportedly exhibited antinociceptive (Koyama et al., 1997),
antioxidative (Zhu et al., 1999), cytotoxic (Guan et al., 2008)
and hepatoprotective activities (Kim et al., 1999), especially
anticancer activity (Jiang et al., 2008; Yao et al., 2012; Das et al.,
2015; Radwan et al., 2015; Shao et al., 2015), which is the most
attractive character of this compound.
Recently, the anticancer activity of GAA attached the
considerable attention of scientists. Recent studies showed that
GAA exhibits antitumor activity on human osteosarcoma (Shao
et al., 2015), lymphoma (Radwan et al., 2015), meningioma
(Das et al., 2015) and breast cancer cells (Jiang et al., 2008)
through suppressing growth and invasive behavior and/or
inducing apoptosis of cancer cells. GAA could also enhance
chemosensitivity of HepG2 cells to Cisplatin (Yao et al., 2012).
Radwan et al. firstly studied the anticancer activity of GAA in vivo
and revealed that GAA can significantly prolong the survival of
EL4 syngeneic mice and decrease tumor metastasis to the liver,
and enhance cell-mediated immune responses by attenuating
myeloid-derived suppressor cells (Radwan et al., 2015). Thus,
GAA can be viewed as a promising anticancer candidate or used
in combination with conventional chemotherapeutic agents for
treatment of cancer.
So far, there is no any published research on the metabolism
of GAA. This study aims to detect and identify GAA metabolites
in vivo by analyzing the bile, plasma and urine after intravenous
administration to rats and in vitro by incubating with rat liver
microsomes (RLMs) and human liver microsomes (HLMs),
analyzing by using a simple and accurate HPLC-DAD-MS/MS
method. Besides, the metabolic kinetics of the main reduction
product of GAAwere determined by a sensitive and rapid UFLC-
MS/MS method.
MATERIALS AND METHODS
Chemicals and Reagents
GAA was purchased from Weikeqi Biotechnology Co, Ltd.
(Chengdu, Sichuan province, China). Ganoderic acid B,
ganoderic acid C2 (GAC2) and ganoderic acid D were kindly
provided by professor Ruo-Yun Chen (Institute of Materia
Medica, Chinese Academy ofMedical Sciences and PekingUnion
Medical College, Beijing, China). Glycyrrhizic acid (GLA), α-
naphthoflavone, quinidine, fluconazole, diethyldithiocarbamate
and uridine 5′-diphosphoglucuronic acid (UDPGA) were
obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO,
USA). Ticlopidine and ketoconazole were purchased from the
National Institutes for Food and Drug Control (Beijing, China).
β-nicotinamide adenine dinucleotide phosphate (NADPH)
was purchased from Roche Molecular Biochemicals (Basel,
Switzerland). A pooled Sprague Dawley rat liver microsomes
(RLMs) was obtained from RILD Research Institute for
Liver Diseases Co. Ltd (Shanghai, China). A pooled human
liver microsomes (HLMs) was obtained from BD Gentest
Corporation (Woburn, MA, USA). Methanol and ethyl acetate
of HPLC grade, and acetonitrile and formic acid of LC/MS
grade, were obtained from Fisher Co. Ltd. (Waltham, MA, USA).
Milli-Q (Millford, MA, USA) water was used throughout the
study.
Animals
Male Sprague-Dawley rats (200 ± 20 g) were supplied by
Beijing Vital Laboratory Animal Technology (Beijing, China).
The animal experiment was approved by the Animal Ethics
Committee at the Institute of Medicinal Plant Development,
Chinese Academy of Medical Sciences. The rats were housed
under standard conditions of temperature (23 ± 2◦C), humidity
(60± 5%) and light (12 h light-dark cycle) in a specific pathogen-
free animal room, and had free access to standard rodent diet and
water before the experiments. On the day before the experiment,
the rats were suffered with light surgeries. Under anesthesia by
an intraperitoneal dose of 10% chloral hydrate at 3.50 ml/kg, a
polyethylene catheter (0.50mm ID, 1.00mmOD, Portex Limited,
Hythe, Kent, England) was cannulated into the right jugular vein
for intravenous drug administration and blood collection, and
another catheter (0.28 mm ID, 0.61 mm OD, Portex Limited,
Hythe, Kent, England) was cannulated into the bile fistul for
bile collection. After surgery, the rats were placed individually in
metabolism cages and allowed to recover for at least 24 h. The
rats were fasted over night with free access to water prior to drug
administration.
Drug Administration and Sample
Preparation
GAA (25mg) was dissolved in 500µl of physiological
saline containing 2% sodium carbonate and diluted with
physiological saline to make the volume of 5 ml (Cheng
C.-R. et al., 2013). The solution was given to rats (n = 5)
intravenously at 20mg/kg through the jugular vein catheter.
After dosing and blood sample collection, 0.2 ml of normal
saline with 20 units of heparin was injected into the body
through the catheter to flush the catheter and prevent blood
coagulation.
Rats were held in metabolism cages, blood was collected into
heparinized tubes from the jugular vein before (blank) and at
5 and 30 min post dosing, and then centrifuged at 1,500 g for
10 min for plasma separation. At the same time, bile and urine
samples were collected before (blank) and over the period of
0–4 h post dosing. All of the collected blank plasma, blank bile,
blank urine, dosing plasma, dosing bile or dosing urine from
five rats were pooled together respectively and stored at −20◦C
until assay.
For plasma, an aliquot of 200 µl sample was mixed with 20
µl HCl solution (1M), and then extracted with 1.5 ml of ethyl
acetate by vortex-mixing for 10 min. The ethyl acetate layer was
collected and concentrated to dryness by a vacuum concentrator.
The residue was reconstituted in 100 µl 80% methanol and
centrifuged at 20,000 g for 15 min. The supernatant was collected
for HPLC-DAD-MS/MS assay. For bile, an aliquot of 150 µl
sample was mixed with 150 µl 80% methanol and 10 µl 5%
formic acid, and then centrifuged at 20,000 g for 15 min. The
supernatant was collected for HPLC-DAD-MS/MS assay. For
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urine, an aliquot of 2ml sample was loaded on a pretreated ODS-
C18 cartridge (Agilent AccuBOND, 500 mg). After washing with
5 ml of water, the cartridge was eluted with 10 ml of methanol.
The methanol eluate was collected and concentrated to dryness
by a vacuum concentrator at 37◦C. The residue was reconstituted
in 200µl 80% methanol and centrifuged at 20,000 g for 15 min,
and the supernatant was collected for HPLC-DAD-MS/MS assay.
In vitro Metabolite Identification
For in vitro metabolites identification, the enzyme incubation
was performed in a medium containing 1.0mg protein /ml
RLMs or HLMs, 100 µM of GAA, 3.3 mM of MgCl2, 3.0
mM of NADPH, 3.0 mM of UDPGA and 100 mM of sodium
phosphate buffer (pH 7.4). The total volume was 500 µl.
The metabolism reaction was initiated by adding NADPH and
UDPGA after 10 min preincubation at 37◦C. The reaction was
maintained at 37◦C for 1 h and terminated by adding with
500 µl of ice-cold acetonitrile. The mixture was centrifuged at
20,000 g for 15 min, and 10 µl of the supernatant was directly
injected for HPLC-DAD-MS/MS assay. Control samples were
prepared as described above by using inactivated enzymes in the
incubation system. Each of the incubations was performed in
duplicate.
Formation Kinetics of the Metabolites M2
and M4
The formation kinetics of the two main reduction metabolites
M2 (GAC2) and M4 (7β,15-dihydroxy-3,11,23-trioxo-lanost-26-
oic acid) were determined. The incubations were performed in
a medium (100 µl) containing 0.25mg protein /ml RLMs or
HLMs, different concentrations of GAA (1–50 µM), 3.3 mM of
MgCl2, 3.0 mM of NADPH and 100 mM of sodium phosphate
buffer (pH 7.4). After 10 min of preincubation, GAA at each
concentration was incubated with RLMs and HLMs for 5 and
30 min, respectively. The reactions were terminated by adding
with 100 µl of ice-cold acetonitrile containing 2 µM GLA used
as internal standard (IS). After centrifugation, metabolites in the
mixture were analyzed by UFLC-MS/MS detection as described
below. The metabolite formation rates vs. GAA concentrations
were plotted to obtain the Michaelis-Menten constant (Km) and
maximum velocity (Vmax) values of the metabolic reactions. Each
of the incubations was performed in triplicate.
Participation of CYP Enzymes in Formation
of the Metabolites M2 and M4
GAA (10 µM) was incubated with 0.25 mg/ml RLMs or HLMs in
the incubation system as described in Section Formation Kinetics
of the Metabolites M2 and M4, in the present or absent of the
following CYP enzymes inhibitors, 10µM α- naphthoflavone (for
CYP1A2), 100 µM ticlopidine (for CYP2C19), 10 µM quinidine
(for CYP2D), 10 µM ketoconazole (for CYP3A), 100 µM
fluconazole (for CYP2C9) and 100 µM diethyldithiocarbamate
(for CYP2E1), respectively. The M2 and M4 formation rates
in the present and absent of inhibitors were compared. The
percentage of inhibition was calculated. Each of the incubations
was performed in triplicate.
HPLC-DAD-MS/MS Conditions for
Metabolite Identification
The identification of metabolites were conducted by a
HPLC-DAD-MS/MS system equipped with an Agilent 1,260
HPLC system (Agilent Technologies, Santa Clara, CA, USA),
1,260 diode array detector (DAD) and 4,500 Q-Trap mass
spectrometer with electrospray ionization source (AB SCIEX,
Framingham, MA, USA). Chromatographic separation was
performed on a C18 column (100 × 4.6 mm, 2.4 µm, BDS
hypersil, Thermo, PA) maintained at 40◦C. The mobile phase
consisted of acetonitrile (A) and 0.1% formic acid aqueous
solution (B) with following gradient elution at a flow rate of
0.40 ml/min: 0–10 min, 20–35% A; 10–20 min, 35% A; 20–25
min, 35–65% A; 25–30 min, 65% A; 30–35 min, 65–20% A; and
35–45 min, 20% A. The DAD spectral data was collected from
190 to 400 nm. The injection volume of all the tested samples
was 10 µl. Mass data were acquired in negative mode under the
following conditions, ion spray voltage −4,500 V, ion source
temperature 450◦C, curtain gas 10 psi, nebulizer gas 60 psi and
auxiliary gas 60 psi. Data were collected using Analyst 1.6.2
(Applied Biosystems) in both first quadrupole (Q1) mass scan
mode and multiple reaction monitoring (MRM) independent
data acquisition (IDA) mode using enhanced product ion scans
(EPI) and enhanced resolution (ER) in the ion trap mode.
UFLC-MS/MS Conditions for Quantitation
of the Metabolites M2 and M4
An LC-MS/MS system consisted of a Shimadzu UFLC system
(Kyoto, JPN) and an AB SCIEX 5500 Q-Trap mass spectrometer
with electrospray ionization source (Foster City, CA, USA). The
chromatographic separation was performed on a C18 column (50
× 2.1 mm, 1.7 µm, Syncronis aQ, Thermo, PA) maintained at
20◦C. The mobile phase consisted of acetonitrile (A) and 0.1%
formic acid aqueous solution (B) with following gradient elution
at a flow rate of 0.30 ml/min: 0–2.50 min, 37% A; 2.50–2.75min,
37–45% A; 2.75–3.75 min, 45% A; 3.75–4.00 min, 45–37% A;
and 4.00–5.00 min, 37% A. Mass spectrometry was adopted in
negative mode, with ion spray voltage −4,500 V, ion source
temperature 550◦C, curtain gas 10 psi, nebulizer gas 55 psi
and auxiliary gas 35 psi. The quantification assay was carried
out by using MRM mode with the precursor-product ion pairs
of m/z 517.3/287.3, 517.3/287.3, 821.4/351.0 for M2, M4, and
GLA, respectively. Declustering potentials were −240 and −32
V, entrance potentials were −10 and −23 V, collision energy
were −50 and −58 V, and cell exit potential were −21 and −16
V for M2/M4 and GLA, respectively. The data acquisition and
peak integration were performed using Analyst software (Version
1.6.2, AB SCIEX).
Metabolic Kinetic Analysis
The kinetic parameters of GAA metabolism by RLMs or HLMs
were calculated by fitting the data to the hyperbolic Michaelis-
Menten model:
V = Vmax ×
[S]
Km + [S]
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Where Vmax is the maximal velocity of formation, S is the
concentration of substrate, Km is the substrate concentration
of half maximal velocity, and the intrinsic clearance (CLint) is
calculated as Vmax/Km.
Statistical Analysis
The statistical difference was performed by Student’s t-test, and
p < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Characterization of GAA Metabolites in
Rats
All of the biological samples were analyzed by HPLC-DAD-
MS/MS for their retention times, UV spectra and mass
fragmentation pathways. Comparing the chromatograms of
MRM survey scan and Q1 full scan of the dosing samples with
their corresponding blank samples, a total of 37 metabolites of
GAA as well as parent GAA (M0) were detected and identified
or tentatively characterized from the bile (34), plasma (22) and
urine (12) samples. Table 1 lists the chromatographic, spectra
and fragment ions data of GAA and its metabolites. Total ion
chromatograms and extracted ion chromatograms of the tested
samples are showed in Figures 1–3.
As shown in Figure 4, the [M−H]− ion m/z 515 of M0
mainly generated the fragment ions at m/z 497, 479, 453,
and 435 by neutral losses of H2O and CO2, and produced
characteristic fragment ions of 301 (b), 300 (b−1), 299
(b−2), 285 (b−H−CH3), 283 (b−H2O) and 195 (d−H−H2O)
by cleavage of D-ring. The metabolites were identified or
tentatively characterized based on their fragmentation pathways
(Supplementary Figures 1–6) and comparison with the parent
compound.
The metabolites M1 (retention time tR = 11.89 min), M2
(tR = 15.54 min), M3 (tR = 16.26 min), and M4 (tR = 18.43
min) all showed a same [M−H]− ion at m/z 517 (Table 1)
with different retention times. Their fragmentation were very
similar to that of GAA and had the product ions at m/z 303
(b), 302 (b−1), 301 (b−2) and 287 (b−H−CH3), all 2 Da
heavier than those of GAA, which were generated from ring D
cleavage. This indicates that the reduction occurred on the A-,
B- or C- rings of M0, that might be 3-carbonyl, 11-carbonyl or
double bond between C-8 and C-9. Among these metabolites,
M2 was found to be the most abundant in vivo (based on the
chromatogram by DAD detector) and identified as GAC2 by
comparing its retention time, UV spectrum and EPI spectrum
with those of GAC2 authentic standard in HPLC-DAD-MS/MS
experiments. With shorter retention time than that of M2, M1
could be inferred as a M2 reduction product, formed by that
the 23-carbonyl group in the side chain of M2 was reduced
into a hydroxyl group and a double bond was simultaneously
formed between C-24 and C-25 (Guo X. et al., 2013). Therefore,
M1 was identified as 3,7β,15,23-tetrahydroxy-11-oxo-lanost-
8,24-dien-26-oic acid. With longer retention times, M3 and
M4 might be inferred to be reduction products of GAA, at
11-carbonyl and double bond between C-8 and C-9, respectively,
and named 7β,11,15-trihydroxy-3,23-dioxo-lanost-8-en-26-oic
acid and 7β,15-dihydroxy-3,11,23-trioxo-lanost-26-oic acid,
respectively, which are reported for the first time. In addition, the
peak response of the metabolites with side chain modification
was found lower than that of the corresponding metabolites
without side chain modification, such as M1<M2, M5<M6,
M17<M18, and M22<M23. It seems that the metabolites with
side chain modification were more unstable than the metabolites
without side chain modification. The peak response of M3 was
higher than that of M4, therefore, M3 might not be side chain
modification metabolite of M4.
Metabolites M5, M6, and M7 exhibited a same [M−H]−
ion at m/z 513, 2 Da lower than the parent GAA. It suggests
that they were all dehydrogenation metabolites of GAA and the
dehydrogenation could occur at the position of 7- or 15- OH.
Metabolite M6 generated m/z 495 and 451 owing to the neutral
loss of H2O and CO2 from the [M−H]
− ion, andm/z 247 owing
to the cleavage of C-ring and a group ions of m/z 301 (b), 283
(b−H2O), and 285 (b−H−CH3), owing to the cleavage of D-
ring. These results indicate that M6might be a 7-hydroxy-15-oxo
derivatives (Yang et al., 2007; Cheng et al., 2012). Compared with
the authentic standard, M6 was identified as ganoderic acid D,
which is the 15-OH dehydrogenation metabolite of GAA. With
the similar mass spectra data, M5 (tR = 21.13 min) exhibited
shorter retention time than M6 (tR = 25.81 min). Therefore, M5
was inferred to be 7β,23-dihydroxy-3,11,15-trioxo-lanost-8,24-
dien-26-oic acid. M7 showed lower polarity with longer retention
time compared to M6, suggesting that the dehydrogenation only
could occur at 7- OH. M7 produced abundant ions at m/z 451,
436, and 421 originating from neutral loss of H2O, CO2 and
CH3 from [M−H]
−, as well as minor fragment ions at 301
(b+2), 285 (b−H−CH3+2) and 247 (a+2). The product ions
of M7 generated from rings cleavage should be at 299 (b), 283
(b−H−CH3) and 245 (a), well, the fragment ions were actually at
301 (b+2), 285 (b−H−CH3+2) and 247 (a+2) for transference
of two hydrogen atoms. The fragmentation pathway of M7 was
in accordance with 7-carbonyl derivatives (Yang et al., 2007),
therefore, M7 was identified as 15-hydroxy-3,7,11,23-tetraoxo-
lanost-8-en-26-oic acid, i.e., ganoderic acid J.
Metabolite M8 gave the [M−H]− ion at m/z 511 with the
greatest intensity, which produced the fragment ions only 2
Da lower than those of M7. Therefore, M8 was identified
as 3,7,11,15,23-pentaoxo-lanost-8-en-26-oic acid, i.e., ganoderic
acid E (Yang et al., 2007; Guo X. et al., 2013).
Metabolites M17 (tR = 15.17 min), M18 (tR = 17.65 min),
and M19 (tR = 18.91 min) gave the same [M−H]
− ions at m/z
515, and produced the characteristic fragment ions at 303 and
249 owing to the cleavage of D-ring and C-ring, respectively, 2
Da heavier than those of M6. The fragmentation pathways of
M17, M18, and M19 were very similar to that of M6, suggesting
that their structures belonged to 7-hydroxy-15-oxo derivatives.
Compared with the authentic standard, M18 was identified as
ganoderic acid B. With shorter retention time than that of
M18, M17 was inferred as M18 isomer at C-17 of side chain,
and named 3,7β,23-trihydroxy-11,15-dioxo-lanost-8,24-dien-26-
oic acid. With longer retention time than that of M18, M19
was inferred as 7β,11-dihydroxy-3,15,23-trioxo-lanost-8-en-26-
oic acid.
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FIGURE 1 | Total ion chromatograms of rat bile samples before (A) and
after intravenous administration of GAA at 20 mg/kg (B).
M20 yielded the [M−H]− ion at m/z 529, and its
corresponding D-ring cleavage fragment ions (b, b−H−CH3)
were 16 Da higher than those of M6, suggesting that M20
occurred hydroxylation reaction on A-, B-, or C- rings. The
most dominant ions at m/z 499 ([M−H−CH2O]
−) and 481
([M−H−H2O−CH2O]
−) in EPI spectrum of M20 resulted
from a neutral loss of CH2O (−30 Da) from the ions at m/z
529 ([M−H]−) and 511 ([M−H−H2O]
−), indicating that an
additional hydroxyl group existed at C-12 of M20. Therefore,
M20 was characterized as 12-hydroxy ganoderic acid D. M20
yielded fragment ion at m/z 193 (d−H−H2O) produced by
D-ring cleavage, which also might be 195 (d−H−H2O+2) for
the transference of two hydrogen atoms by 15-carbonyl. It is
reported that fragment ion at m/z 193 indicated metabolites
possessed a hydroxyl group at C-20 (Guo et al., 2012). Well,
in the structure identification of M20, the 193 fragment ion
was not a signature fragment for hydroxylation at C-20. Only
when the fragment signals (b, b−H−CH3, and so on) resulted
from D-ring cleavage of hydroxylation metabolites were similar
to those of parent compound, suggesting that they possessed
the same structure of A-, B- and C- rings as that of parent
compound with no hydroxylation reaction, the 193 fragment
would be a characteristic fragment ion indicating an extra
hydroxyl group at C-20.
M21 showed a [M−H]− ion at m/z 515, with similar
fragmentation pathway to that of M0. After the prominent loss
of H2O and CO2, mass fragmentation occurred on the ring
skeleton, generating the ions at m/z 301, 300, 299, and 285.
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FIGURE 2 | Extracted ion chromatograms of GAA metabolites in rat bile sample after intravenous administration of GAA at 20mg/kg.
Minor ions at 303 (b+2) and 286 (b+1−H−CH3) were also
observed, indicating that C-7 of M21 was oxidized to form
a carbonyl group. In addition, M21 showed longer retention
time (24.22min) than that of M0 (22.69 min), indicating that
M21 wasn’t reduced at C-3. Therefore, M21 was identified as
11,15-dihydroxy-3,7,23-trioxo-lanost-8-en-26-oic acid.
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FIGURE 3 | Extracted ion chromatograms of GAA hydroxylation metabolites in plasma and GAA oxidoreduction metabolites in urine. (A) Blank plasma;
(B) plasma sample after intravenous administration of GAA at 20 mg/kg; (C) blank urine; (D) urine sample after intravenous administration of GAA at 20mg/kg.
The EPI spectra of M9, M10, M11, M12, and M35 showed
their [M−H]− ions all at m/z 531. The major D-ring cleavage
fragment ions (b, b−H−CH3, and so on) of M9 and M10
were 16 Da higher than those of M0 and M21, respectively,
indicating that hydroxylation reaction occurred on A-, B-, or
C- rings. In MS spectra of M9 and M10, the neutral loss
of CH2O (30 Da) from ions at m/z 531 ([M−H]
−) and 513
([M−H−H2O]
−) yielded the dominant fragment ions at m/z
501 and 483, respectively, suggesting the presence of 12-OH
(Yang et al., 2007; Guo X.-Y. et al., 2013). Therefore, M9
and M10 were characterized as 12-hydroxy ganoderic acid A
and 11,12,15- trihydroxy-3,7,23-trioxo-lanost-8-en-26-oic acid,
respectively. M35 produced similar major D-ring cleavage
fragment ions with those of M9 except the absence of ions at
m/z 501 and 483, suggesting that M35 occurred hydroxylation
reaction on A-, B-, or C- rings while lacked 12-OH. Since the
angular methyl group easily undergo hydroxylation reaction
(Yang et al., 2007; Cheng et al., 2012; Guo X. et al., 2013), M35
was proposed as 28 (29)-hydroxy ganoderic acid A. The fragment
signals resulted from D-ring cleavage of M11 and M12 were
similar to those of M0 and M21, respectively, suggesting that
they possessed the same structure of A-, B-, and C- rings as that
of M0 and M21, accordingly. The spectra showed characteristic
fragment ion at m/z 193 (d−H−H2O−H2O), indicating that
M11 and M12 possessed an extra hydroxyl group at C-20
(Guo et al., 2012). Therefore, M11 and M12 were inferred as
20-hydroxy ganoderic acid A and 11,15,20-trihydroxy-3,7,23-
trioxo-lanost-8-en-26-oic acid, respectively.
M13, M14, M15, and M16 gave the same [M−H]− ions at
m/z 533. M14 showed fragment ions at m/z 303 (b), 301 (b−2)
and 287 (b−16), suggesting that it possessed the same structure
of A-, B-, and C- rings as that of M2. Characteristic fragment
ion at m/z 193 was observed, indicating the presence of 20-OH.
Therefore, M14 was inferred as 20-hydroxy ganoderic acid C2.
The major D-ring cleavage fragment ions (m/z 319, 317, and
303) of M15 were 16 Da higher than those of M2, indicating that
hydroxylation reaction occurred on A-, B-, or C- rings. In EPI
spectrum of M15, the key fragment ions at m/z 485 and 467,
owing to a neutral loss of CH2O (30 Da) from the ions atm/z 515
([M−H−H2O]
−) and 497 ([M−H−H2O−H2O]
−), respectively,
were detected, indicating the presence of 12-OH. Therefore, M15
was identified as 12-hydroxy ganoderic acid C2. M13 produced
similar fragment ions with those of M15 except the absence of
ions at m/z 485 and 467, suggesting M13 lacked 12-OH. In its
spectrum, the characteristic product ion at m/z 195 indicated
that M13 possessed the same side chain as that of M2. According
to that the angular methyl groups easily undergo hydroxylation
reactions, M13 was tentatively identified as 3,7β,15,28(29)-
tetrahydroxy-11,23-dioxo-lanost-8-en-26-oic acid. The
fragmentation pathway of M16 was very similar to that of M15
with the fragment ions at m/z 485 ([M−H−H2O−CH2O]
−),
467 ([M−H−H2O−H2O−CH2O]
−), 317 (b−2) and 303
(b−H−CH3), while, retention time of M16 (tR =13.42 min)
was longer than that of M15 (tR = 12.46min). Thus, M16
was tentatively identified as 7β,11,12, 15-tetrahydroxy-3,
23-dioxo-lanost-8-en-26-oic acid.
M23 had a [M−H]− ion at m/z 595, and produced abundant
[M−H−SO3]
− ion at m/z 515 by the neutral loss of 80 Da and
other major fragment ions, which were very similar with those of
M0. This suggests that it was sulfation ofM0, and the sulfuric acid
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FIGURE 4 | The mass spectrum and proposed fragmentation pathways of GAA.
moiety could be in conjunction with 7- or 15- OH. Ganoderic
acid A 7-O-sulfation had stronger polarity than ganoderic acid
A 15-O-sulfation for relatively weak intramolecular hydrogen
bonds, and could be easily generated. Therefore, M23 was
tentatively identified as ganoderic acid A 7-O- sulfation. In
the same way, M24 (m/z, 597) was inferred as ganoderic acid
C2 3-O-sulfation. The major fragment ions of M22 (m/z, 595)
were the same as M23. While, its polarity was even stronger
than M24 (tR = 8.51min), with retention time being 7.85 min,
indicating that the difference in structure between M22 and
M23 was on the side chain. Therefore, M22 was inferred as
15,23-dihydroxy-3,11-dioxo-lanost-8,24-dien-26-oic acid-7β-O-
sulfation.
The EPI spectra of M25, M26, and M27 showed the
same [M−H]− ion at m/z 693, which produced abundant
[M−H−GlcA]− ion at m/z 517 by neutral loss of 176 Da
and their other characteristic fragment ions were similar with
those of GAC2. This suggested that they were monoglucuronide
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FIGURE 5 | Proposed metabolic pathways of GAA in rats and structures of its metabolites.
of GAC2 and the glucuronic acid moiety could conjunct
with 3-, 7-, or 15- OH, respectively. The glucuronic acid
moiety at 15-OH of GAC2 could form stronger intramolecular
hydrogen bond than that at 7-OH, which would lower their
polarities than that of ganoderic acid C2 3-O-glucuronide.
Therefore, M25, M26, and M27 were tentatively characterized
as ganoderic acid C2 3-O-glucuronide, ganoderic acid C2
7-O-glucuronide and ganoderic acid C2 15-O-glucuronide,
respectively (Guo X.-Y. et al., 2013), in combination of their
retention time.
The EPI spectra of M28, M29, M30, and M31 showed
[M−H]− ion at 691. By comparing the similarity of their
major fragment ions with those of M0 and M21, it suggested
that M28 and M30 were monoglucuronide of M0, and M29
and M31 were monoglucuronide of M21. Therefore, M28,
M29, M30, and M31 were inferred to be ganoderic acid A
7-O-glucuronide, 15-hydroxy-3,7,23-trioxo-lanost-8-en-26-oic
acid-11-O-glucuronide, ganoderic acid A 15-O-glucuronide
and 11-hydroxy-3,7,23-trioxo-lanost-8-en-26-oic acid-15-O-
glucuronide, respectively, dependent on their polarities.
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M32 and M33 gave [M−H]− ions both at m/z 547, and
their fragmentation pathways were very similar to that of M0,
suggesting that they were dihydroxylation of GAA. In EPI
spectrum of M32 and M33, the neutral loss of CH2O (30 Da)
from ions at m/z 547 ([M−H]−) and 529 ([M−H−H2O]
−)
yielded the dominant fragment ions at m/z 517 and 499,
respectively, suggesting the presence of 12-OH. The key fragment
ions at m/z 303 (b−CH2O) and 287 (b−H−CH3−CH2O)
generated from the D-ring cleavage and neutral loss of CH2O
in the spectrum of M32, meaning the b and b−H−CH3 being
333 and 317, respectively, indicated that the other hydroxylation
occurred on an angular methyl group of ring A, C-28 or C-29.
Therefore, M32 was inferred as 12, 28(29)-dihydroxy ganoderic
acid A. In the spectrum of M33, the major D-ring cleavage
fragment ions (m/z 317 and 301) were 16 Da higher than those
of M0, indicating that only one hydroxylation reaction occurred
on A-, B-, or C- rings, in addition, characteristic fragment
ions at m/z 211 (d−H−H2O) and 193 (d−H−H2O−H2O)
were observed, indicating the presence of 20-OH. Thus, M33
was inferred as 12, 20-dihydroxy ganoderic acid A. M34 (m/z,
563) was trihydroxylation of ganoderic acid A for the same
fragmentation pathway as M0. M34 exhibited ions at m/z
533 ([M−H−CH2O]
−), 515 ([M−H−H2O−CH2O]
−),
303 (b−CH2O), 287 (b−H−CH3−CH2O) and 193
(d−H−H2O−H2O), indicating the presence of 12, 20, 28
(29)-OH. Thus, M34 was tentatively characterized as 12, 20, 28
(29)-trihydroxy ganoderic acid A.
The EPI spectra of M36 and M37 showed [M−H]− ions
at m/z 534, which produced abundant [M−H−CO]− ions at
m/z 515 originating from neutral losses of 28 Da, suggesting
the presence of 12-carbonyl. The [M−H−CO]− ions of M36
and M37 showed the same fragmentation patterns as those of
M0 and M21, respectively. The key fragment ions at m/z 301
(b−CO) and 285 (b−H−CH3−CO) generated from the D-
ring cleavage and neutral loss of CO in the spectrum of M36,
meaning the b and b−H−CH3 being 329 and 313, respectively,
indicated that another carbonyl on an angular methyl group
of ring A, C-28 or C-29. Therefore, M36 was inferred to be
12,28(29)-dicarbonyl ganoderic acid A. In the same way, M37
was inferred to be 11,15-dihydroxy-3,7,12,23,28(29)-pentaoxo-
lanost-8-en-26-oic acid. The –CH=O of M36 and M37 might
be formed from M0 and M21, respectively, which firstly suffered
hydroxylation at C-12 and C-28(29), and then dehydrogenation
to form two carbonyls.
Characterization of GAA Metabolites
Produced by RLMs and HLMs
The metabolites found in RLMs incubations were similar
with those detected in the bile after i.v. dose. Except
for the monohydroxylated metabolites M9 and M11, the
phase II metabolite M28 formed by glucuronidation was
also found. The metabolite M2 was the most abundant
metabolite in RLMs incubations, therefore, the relevant M2
metabolites were detected, including two mono-hydroxylated
derivatives (M13 and M15) and one glucuronide conjugated
derivative (M25).
The metabolites detected in HLMs incubations were fewer
than those found in RLMs incubations, including two reduced
metabolites (M2 and M4), three monohydroxylated metabolites
(M9, M11, andM35) and one glucuronide conjugated metabolite
(M28). Both M2 and M4 were abundant in HLMs incubations.
However, M4 was very minor in rats and undetected in RLMs
incubations.
Proposed GAA Metabolic Pathway
By using HPLC-DAD-MS/MS techniques, a total of 37
metabolites were identified or tentatively characterized from the
bile (34), plasma (22) and urine (12) samples of rats after i.v.
dose of GAA. The results reveal that hepatocyte metabolism is
the major route of clearance for GAA. The metabolic pathways
of the in vitro samples were in consistent with those of the in
vivo samples for rats. Nine metabolites (Table 1) were detected
in RLMs reaction medium. The metabolites detected in RLMs
were also found in the in vivo samples, indicating the metabolism
consistency of GAA in vitro and in vivo for rats. For predicting
GAA metabolism in humans and understanding the enzymes
involved in drug metabolism differing between humans and
rats, the identification of metabolites in HLMs was conducted.
The GAA metabolites generated in HLMs were also observed
in those in vitro and in vivo samples from rats, indicating the
presence of the similar pathway of GAA metabolism in humans
and rats.
Proposedmetabolic pathways of GAA are showed in Figure 5.
Both phase I and phase II metabolites were observed. The phase I
metabolism in rats involved reduction, oxidation, oxidoreduction
and hydroxylation. The reduction product, ganoderic acid C2,
was the most abundant. Extensive hydroxylation products of
GAA or its reduction/oxidation metabolites were observed in
the bile and plasma. The phase II biotransformation observed
included glucuronidation, and sulfation. There were a group
of glucuronidation and sulfation metabolites of parent GAA
and its reduction/oxidation metabolites in bile, and abundant
glucuronidation metabolites of GAA and its reduction/oxidation
metabolite in urine. Few glucuronidation metabolites were
detected in plasma. These data indicated that the phase II
metabolites were primarily excreted into the bile and urine.
GAA is composed of a highly oxygenated tetracyclic ring
skeleton and an acidic side chain. The hydroxyl groups at C-3,
C-7, and C-15 in GAA and its metabolites could be oxidized into
carbonyl groups or conjugated with glucuronic acid and sulfuric
acid. The carbonyl groups at C-3 and C-11 could be reduced to
hydroxyl groups. The C-12, C-20, and C-28 (29) of GAA and
its oxidoreduction metabolites were easily hydroxylated. The side
chains at C-17 of GAA and its metabolites could be isomerized.
Therefore, themainmetabolic soft spots in the chemical structure
of GAA were the 3, 7, 11, 15, 23- carbonyl groups (or hydroxyl
groups) and 12, 20, 28 (29)- carbon atoms.
Formation Kinetics of the Metabolites M2
and M4
The reduction metabolites were found to be the most abundant
both in vivo and in vitro. Their formation kinetics in RLMs
and HLMs were examined to further explore the differences
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FIGURE 6 | Formation kinetics of GAA metabolites M2 and M4 in
pooled RLMs (A) or HLMs (B,C). (mean ± SD, n = 3).
in reduction metabolism between RLMs and HLMs. The major
reduction metabolite was M2 in RLMs, whereas M2 and M4 in
HLMs. The kinetics of bothM2 andM4 in RLMs and HLMs were
fitted to the Michaelis-Menten equation. The kinetic parameters
of M2 in RLMs were estimated as Km of 28.80 µM, Vmax of
185.81 pmol/min/mg, and Clint of 6.45 µl/min/mg. The kinetic
parameters ofM2 andM4 inHLMswere estimated as Km of 91.81
and 6.12 µM, Vmax of 30.18 and 29.70 pmol/min/mg, and Clint
of 0.33 and 4.85 µl/min/mg, respectively. The Lineweaver-Burk
FIGURE 7 | Effect of CYP inhibitors on the formation of GAA
metabolites M2 and M4 in pooled RLMs (A) or HLMs (B). GAA was
incubated with pooled RLMs or HLMs with and without α-naphthoflavone
(NAP), ticlopidine (TIC), quinidine (QND), ketoconazole (KET), fluconazole (FLU)
and diethyldithiocarbamate (DIE). *p < 0.05, ***p < 0.001, compared vs.
control. (mean ± SD, n = 3).
transformation revealed a monophasic plot (Figure 6). The Km
value of M2 generated by HLMs was approximately 3-fold
higher than that by RLMs. The Vmax and CLint values of M2
formation by RLMs were 6-fold and 20-fold higher than those
by HLMs, respectively, suggesting that M2 was formated faster
in RLMs than in HLMs. In HLMs, The Km value of M2 was
15-fold higher than that of M4. The Vmax values of M2 and
M4 were similar. The CLint of M4 formation was 15-fold higher
than that of M2, suggesting that M4 was formated faster than
M2 in HLMs.
Participation of CYP Enzymes in Formation
of the Metabolites M2 and M4
The effects of six selective inhibitors of CYP enzymes on
the formation of M2 and M4 were evaluated in vitro, and
the results are showed in Figure 7. Ketoconazole (10 µM), a
CYP3A inhibitor, could significantly inhibit the formation of
M2 in RLMs by 19.91%, and strongly inhibit the formation
of M2 and M4 in HLMs by 55.99 and 38.25%, respectively.
Other inhibitors could not produce significant effects on the
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formation of the two metabolites. These data suggested that
the formation of M2 and M4 might be mainly catalyzed by
CYP3A enzyme.
CONCLUSIONS
GAA could undergo extensive metabolism, including reduction,
oxidation, and hydroxylation phase I metabolism, and
glucuronidation and sulfation phase II metabolism. Its main
metabolic soft spots were 3, 7, 11, 15, 23-carbonyl groups
(or hydroxyl groups) and 12, 20, 28 (29)-carbon atoms. The
reduction metabolism were catalyzed by CYP3A isoenzyme
both in RLMs and HLMs, but with different kinetics. These
results will be valuable for understanding the mechanism of
pharmacological activities and further pharmacokinetic studies
of GAA.
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